Sentence examples for propensity to relapse from inspiring English sources

Control of impulsive behavior is a critical factor in the propensity to relapse (Moeller et al, 2001b).

Since current regimens are not ideal due to short- and long-term toxicity and propensity to relapse after treatment withdrawal, we developed a treatment protocol based on a novel combination of rituximab and cyclosporine that targets both the B-cell and T-cell limbs of the immune system.

In particular, the impaired control over the use of the substance and propensity to relapse long after withdrawal symptoms suggest that a behavioural disorder, such as substance dependence, play a major role in promoting and maintaining MOH [16].

A Src-related signature has also been proposed to segregate primary breast tumors based on their propensity to relapse to bone [ 9].

Therefore, impulse control deficits are associated with the propensity to seek cocaine compulsively (Belin et al., 2008) and the propensity to relapse after abstinence.

Importantly, like the DSM-IV criteria for human addiction, these behaviours have prognostic value, and their presence predicted a higher propensity to relapse.

In our study, however, we could not link Th17 expansion to relapse propensity.

Thus, high expression levels of MMR components may exert a positive influence both on the propensity of chemotherapy-naive tumors to relapse (perhaps because MMR limits the accumulation of additional genetic alterations) and on the probability that neoplasms exposed to CDDP become chemoresistant.

This was predictable, taking into account the nature of the study in which the selection mechanism tended to exclude from randomization biologically aggressive tumours with a high propensity to early relapse.

This study uses US administrative claims data and propensity score matching (PSM) to compare relapse rates and time to relapse among patients with MS using either platform therapy or natalizumab.

We used propensity score matching (PSM) to compare relapse rates and time to relapse among commercially insured patients with MS who were administered platform therapy or natalizumab for 12 months.